Stocks | |
On a recent weekend trip, I was made aware that the future was closer to reality than I thought. While walking through the city, I did a double-take when my son said, “Dad, why does my phone say 5G?”
I took out my phone and there it was in the upper left-hand corner of my screen... Read the Full Story >> |
|
From Our PartnersThis new type of Internet could change everything in the coming years...But your chance to profit from it could start in the coming days! | Click here for full details. |
|
The Early Bird Stock Of The Day Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. | View Today's Stock Pick |
|